Home › Research › Treatments
Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
Ebell MH, Barry HC, Baduni K, Grasso G. Annals of Family Medicine, 2024
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Purpose We conducted a meta-analysis to evaluate clinically meaningful benefits and harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia. Methods We searched PubMed, Cochrane CENTRAL, and 5 trial registries, as well as the reference lists of identified studies. We included randomized controlled trials comparing a monoclonal antibody with placebo at a dose consistent with that used in phase 3 trials or for Food and Drug Administration approval. Studies had to report at least 1 clinically relevant benefit or harm. Data were extracted independently by at least 2 researchers for random effects meta-analysis. Changes in cognitive and functional scales were compared between groups, and each difference was assessed to determine if it met the minimal clinically important difference (MCID). Results We identified 19 publications with 23,202 total participants that evaluated 8 anti-amyloid antibodies. There were small improvements over placebo in the Alzheimer's Disease Assessment Scale (ADAS)-Cog-11 to -14 score (standardized mean difference = -0.07; 95% CI, -0.10 to -0.04), Mini Mental State Examination score (0.32 points; 95% CI, 0.13 to 0.50), and Clinical Dementia Rating-Sum of Boxes scale score (mean difference =-0.18 points; 95% CI, -0.34 to -0.03), and the combined functional scores (standardized mean difference = 0.09; 95% CI, 0.05 to 0.13). None of the changes, including those for lecanemab, aducanumab, and donanemab, exceeded the MCID. Harms included significantly increased risks of amyloid-related imaging abnormalities (ARIA)-edema (relative risk [RR] = 10.29; number needed to harm [NNH] = 9), ARIA-hemorrhage (RR = 1.74; NNH = 13), and symptomatic ARIA-edema (RR = 24.3; NNH = 86). Conclusions Although monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales in patients with Alzheimer dementia, these improvements are far below the MCID for each outcome and are accompanied by clinically meaningful harms.
What this study adds
Evidence grade: High
This is a pooled review of 23,202 participants. This meta-analysis of 19 publications with 23,202 participants found small improvements over placebo on some cognitive and functional scales with anti-amyloid antibodies, but none of the differences met the minimal clinically important difference. Reported effect size: CDR-SB mean difference -0.18 (95% CI -0.34 to -0.03), below the MCID; ARIA-oedema NNH 9.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ebell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024). Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. Annals of Family Medicine. https://doi.org/10.1370/afm.3050
Vancouver
Ebell MH, Barry HC, Baduni K, Grasso G. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis. Annals of Family Medicine. 2024. doi:10.1370/afm.3050. PMID: 38253509.
BibTeX
@article{ebell2024-38253509,
author = {Ebell, M. H. and Barry, H. C. and Baduni, K. and Grasso, G.},
title = {{Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis}},
journal = {Annals of Family Medicine},
year = {2024},
doi = {10.1370/afm.3050},
pmid = {38253509},
url = {https://doi.org/10.1370/afm.3050}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results We identified 19 publications with 23,202 total participants that evaluated 8 anti-amyloid antibodies.
- Harms included significantly increased risks of amyloid-related imaging abnormalities (ARIA)-edema (relative risk [RR] = 10.29; number needed to harm [NNH] = 9), ARIA-hemorrhage (RR = 1.74; NNH = 13), and symptomatic ARIA-edema (RR = 24.3; NNH = 86).
Why it matters
This meta-analysis of 19 publications with 23,202 participants found small improvements over placebo on some cognitive and functional scales with anti-amyloid antibodies, but none of the differences met the minimal clinically important difference. It also found significantly increased risks of amyloid-related imaging abnormalities, so the benefits appear small and come with harms.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants23,202
- Effect sizeCDR-SB mean difference -0.18 (95% CI -0.34 to -0.03), below the MCID; ARIA-oedema NNH 9
- Evidence strengthHigh
Limitations
Pools drugs with different efficacy; MCID thresholds are debated; does not model longer-term or subgroup (e.g. low-tau) effects.
How this study scored 74/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. We have no data on senior author's track record and free to read, so those were left out: it earned 70 of the 94 points we could judge it on, which is 74 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Annals of Family Medicine) |
| Journal's citation record | 2 / 4 | The Annals of Family Medicine: journal h-index 161 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 23,202 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 4 / 7 | Cited 98 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 24.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 3 / 6 | Cited 7.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 9 other studies in this library |
| Still being cited | 3 / 4 | Cited 98 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Gabrielle Grasso holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 1 / 3 | Michigan State University: institution h-index 1,089 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38253509) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 70 / 94 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 70 of the 94 points we could judge it on is 74 out of 100. |
| Total | 74 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.
Later studies that cite this one
9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.